Multidrug-Resistant Clinical Infections; Results from a Point Prevalence Study in a Tertiary Resource-Limited Hospital, South-West Nigeria
Keywords:
Antimicrobial resistance, Multidrug-resistant organisms, Multidrug-resistant infectionsAbstract
Multidrug-resistant (MDR) infections are on the rise globally, often exhibiting significant geographical variability and posing a great threat especially in the low- and middle-income countries. We aimed at investigating the prevalence and patterns of MDR clinical infections in our local Hospital. This was a point prevalence study involving admitted patients in our hospital, following routine sample processing, data was extracted from the microbiology processing forms and clinical files of the patients using a well-structured proforma. Ethical approval was sought and obtained for the study. Analysis was done with the IBM Statistical Package for Social Sciences (SPSS) version 22. There were 101 patients with complete documentation. The age range was from 2 – 65 years, with 58 (57.4%) female and 43 (42.6%) male. There were 17 isolated organisms, of these, 13 (76.5%) were multidrug-resistant. No significant association was found between sex, age, and sub-specialties of the patient and MDR infections. The overall prevalence of MDR infections found among the patients was 12.9%. and more common among the males (61.5%). More MDR infections were recorded among patients in Nephrology subspecialties. The common isolates were S. aureus (n=6, 35.3%), then E. coli (n=3, 17.6%), P. aeruginosa (n=5, 29.4%), Klebsiella spp. (n=6, 17.6%), 76.5% of these organisms were MDRO. The study documents prevalent high multidrug-resistant bacterial infections, calling for urgent and improved effort in the implementation of infection control measures and antibiotic stewardship in our hospitals so as to limit the spread of multidrug-resistant bacteria.
References
1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012 Mar 1;18(3):268–81.
2. WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. [cited 2025 Feb 10]. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed [Accessed 2025 Feb 10].
3. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Frontiers in microbiology. 2019 Apr 1;10:539.
4. Palma E, Tilocca B, Roncada P. Antimicrobial resistance in veterinary medicine: An overview. International journal of molecular sciences. 2020 Mar 11;21(6):1914.
5. Christaki E, Marcou M, Tofarides A. Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. Journal of molecular evolution. 2020 Jan;88(1):26-40.
6. Dadgostar P. Antimicrobial resistance: implications and costs. Infection and drug resistance. 2019 Dec 20:3903-10.
7. Oladele R, Akanmu L, Adeleke G, Ettu AW, Adetifa K, Peters C, Njagua EN, Ogunsola F. Antimicrobial resistance pattern in two intensive care units in a resource limited setting. International Journal of Infectious Diseases. 2022 Mar 1;116:S14.
8. Parascandalo FA, Zarb P, Tartari E, Lacej D, Bitincka S, Manastirliu O, Nika D, Borg MA. Carriage of multidrug-resistant organisms in a tertiary university hospital in Albania—a point prevalence survey. Antimicrobial Resistance & Infection Control. 2016 Dec;5:1-6.
9. Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microbial Drug Resistance. 2016 Jul 1;22(5):412-31.
10. Mukhopadhyay S, Bharath Prasad AS, Mehta CH, Nayak UY. Antimicrobial peptide polymers: No escape to ESKAPE pathogens—A review. World Journal of Microbiology and Biotechnology. 2020 Sep;36:1-4.
11. Olowo-Okere A, Ibrahim YK, Nabti LZ, Olayinka BO. High prevalence of multidrug-resistant Gram-negative bacterial infections in Northwest Nigeria. Germs. 2020 Dec 28;10(4):310.
12. Makanjuola OB, Fayemiwo SA, Okesola AO, Gbaja A, Ogunleye VA, Kehinde AO, et al. Pattern of multidrug resistant bacteria associated with intensive care unit infections in Ibadan, Nigeria. Ann Ib Postgrad Med [Internet]. 2018 [cited 2024 Mar 24];16(2):162–9. Available from: https/www.ajol.info/index.php/aipm/article/view/183714
13. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2021.
14. Gnimatin JP, Weyori EW, Agossou SM, Adokiya MN. Bacterial infections epidemiology and factors associated with multidrug resistance in the northern region of Ghana. Sci Rep. 2022;12(1).
15. Rodríguez-Villodres Á, Martín-Gandul C, Peñalva G, Guisado-Gil AB, Crespo-Rivas JC, Pachón-Ibáñez ME, Lepe JA, Cisneros JM. Prevalence and risk factors for multidrug-resistant organisms colonization in long-term care facilities around the world: a review. Antibiotics. 2021 Jun 7;10(6):680.
16. Cassone M, Mody L. Colonization with multidrug-resistant organisms in nursing homes: scope, importance, and management. Current geriatrics reports. 2015 Mar;4:87-95.
17. Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Scientific reports. 2020 Jul 29;10(1):12689.
